Secreted phospholipase A2 group X (sPLA 2 -X) is one of the most potent enzymes of the phospholipase A 2 lipolytic enzyme superfamily. Its high catalytic activity toward phosphatidylcholine (PC), the major phospholipid of cell membranes and lowdensity lipoproteins (LDL), has implicated sPLA 2 -X in chronic inflammatory conditions such as atherogenesis. We studied the role of sPLA 2 -X enzyme activity in vitro and in vivo, by generating sPLA 2 -X-overexpressing macrophages and transgenic macrophage-specific sPLA 2 -X mice. Our results show that sPLA 2 -X expression inhibits macrophage activation and inflammatory responses upon stimulation, characterized by reduced cell adhesion and nitric oxide production, a decrease in tumor necrosis factor (TNF), and an increase in interleukin (IL)-10. These effects were mediated by an increase in IL-6, and enhanced production of prostaglandin E 2 (PGE 2 ) and 15-deoxy-⌬12,14-prostaglandin J 2 (PGJ 2 ). Moreover, we found that overexpression of active sPLA 2 -X in macrophages strongly increases foam cell formation upon incubation with native LDL but also oxidized LDL (oxLDL), which is mediated by enhanced expression of scavenger receptor CD36. Transgenic sPLA 2 -X mice died neonatally because of severe lung pathology characterized by interstitial pneumonia with massive granulocyte and surfactant-laden macrophage infiltration. We conclude that overexpression of the active sPLA 2 -X enzyme results in enhanced foam cell formation but reduced activation and inflammatory responses in macrophages in vitro. Interestingly, enhanced sPLA 2 -X activity in macrophages in vivo leads to fatal pulmonary defects, suggesting a crucial role for sPLA 2 -X in inflammatory lung disease.